Moreover, the treatment with MTX was associated with increased serum concentration of B cell activating factor (BAFF) in patients with systemic lupus erythematosus (SLE), which may be due to the diminished uptake by the impaired B cells (29). This evidence concerns the gene TNFSF13B and systemic lupus erythematosus.